再鼎醫藥-SB(09688.HK):完成發售美國預託股份
格隆匯 4 月 25日丨再鼎醫藥-SB(09688.HK)公佈,公司已向美國證交會提交8-K表格,內容有關其完成於美國包銷發售477.6萬股美國預託股份,而每股美國預託股份代表一股公司普通股,價格為每股美國預託股份150.00美元。公司亦已授予美國預託股份發售包銷商30日選擇權,以按發售價(扣除包銷折扣及佣金)額外購買最多71.64萬股美國預託股份。包銷商已悉數行使彼等之選擇權以購買該等額外美國預託股份。美國預託股份發售已於2021年4月23日(美國東部時間)完成。
公司的預期全球發售所得款項總額(包括美國預託股份發售及先前宣佈有關22.4萬股普通股的包銷發售))合共約為8.575億美元。公司來自美國預託股份發售的所得款項總額(未扣除包銷折扣及佣金以及其他發售開支)約為8.239億美元。
普通股發售預期將於2021年4月28日(香港時間)或前後完成,並將以港元結算,價格為每股普通股1,164.20港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.